Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Relmada Therapeutics announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8 to 10. The company is a clinical-stage biotechnology firm focused on developing therapies for oncology and CNS disorders, with lead candidates NDV-01 and sepranolone.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.